bosulif

Showing 6 posts of 6 posts found.

Pfizer’s Bosulif scores US green light in leukaemia sub-type

December 21, 2017
Sales and Marketing FDA, Pfizer, bosulif, leukaemia, leukemia, pharma

Pfizer has revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in the …

NICE approves lung cancer and leukaemia treatments

August 24, 2016
Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed

The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

July 7, 2016
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …

Pfizer gets early approval for breast cancer drug

February 4, 2015
Sales and Marketing FDA, Pfizer, Xalkori (crizotinib), axitinib, bosulif, bosutinib, femara, ibrance, inlyta, letrozole, palbociclib

The FDA has shown Pfizer’s breast cancer drug Ibrance an early green light to treat patients who are at the …

Pfizer image

NICE rejects Bosulif

November 28, 2013
Sales and Marketing CML, NHS, NICE, Pfizer, bosulif

 In a blow for Pfizer NICE has categorically rejected the manufacturer’s Bosulif as a treatment for previously-treated chronic myeloid leukaemia …

pfizer image

NICE rejects Pfizer blood cancer drug

July 16, 2013
Sales and Marketing BMS, CML, NICE, Pfizer, bosulif

NICE is not recommending Pfizer’s blood cancer drug Bosulif due to uncertainties over its cost effectiveness and survival benefit. In …

The Gateway to Local Adoption Series

Latest content